Opinion
‘We Need to Rethink Our Options’: Lung Cancer Recurrence
- Author:
- Mark G. Kris, MD
“Suddenly, we have better tools to control systemic spread.”
News
Unlikely Breakthrough of the Year: Chemo for Lung Cancer
- Author:
- Mark G. Kris, MD
Dr. Mark Kris discusses the importance of chemotherapy in lung cancer treatment.
Opinion
How to think about second-line therapy in NSCLC
- Author:
- Mark G. Kris, MD
We really have to do better.
Opinion
Neoadjuvant advantages: Treating locally advanced lung cancer
- Author:
- Mark G. Kris, MD
I think that it’s time to change some of our standards. When patients appear with lung cancers other than tiny ones that might be detected through...
Opinion
New ‘C word’: Cure should be the goal for patients with lung cancer
- Author:
- Mark G. Kris, MD
I didn’t hear it at ASCO, but the truth of the matter is that’s a word we should be using and be using more.
Opinion
Standard-of-care therapy in lung cancer: Be open to new ideas
- Author:
- Mark G. Kris, MD
There’s no doubt that our outcomes are better for patients, but it’s much harder to make the best choice and I think there’s more pressure on us...
Opinion
Postop RT: Meaningful survival improvement in N2 lung cancer
- Author:
- Mark G. Kris, MD
“When you have patients with N2 disease, after the completion of systemic therapies, think about the use of PORT and get the advice of a radiation...
Opinion
ctDNA shows promise for assessing lung cancer treatment response
- Author:
- Mark G. Kris, MD
These are critical therapies because they are given with the intention of improving the chance for cure.
Opinion
Alleviating chemo-related nausea is a huge unmet need
- Author:
- Mark G. Kris, MD
We control nausea in only half of the patients who receive cisplatin in 2022. That is a huge issue.
Article
Highlights in Non–Small Cell Lung Cancer From ASCO 2020
- Author:
- Mark G. Kris, MD
Dr. Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody‒...